Cargando…

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer

BACKGROUND: Following curative-intent neoadjuvant therapy in locally advanced rectal cancer, metastatic progression is still dominant. We investigated if patients’ circulating 25-hydroxyvitamin D [25(OH)D] levels were associated with outcome. METHODS: Serum 25(OH)D concentration was assessed by liqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrahamsson, Hanna, Porojnicu, Alina C., Lindstrøm, Jonas C., Dueland, Svein, Flatmark, Kjersti, Hole, Knut H., Seierstad, Therese, Moan, Johan, Redalen, Kathrine Røe, Meltzer, Sebastian, Ree, Anne Hansen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533753/
https://www.ncbi.nlm.nih.gov/pubmed/31122213
http://dx.doi.org/10.1186/s12885-019-5724-z
_version_ 1783421278648008704
author Abrahamsson, Hanna
Porojnicu, Alina C.
Lindstrøm, Jonas C.
Dueland, Svein
Flatmark, Kjersti
Hole, Knut H.
Seierstad, Therese
Moan, Johan
Redalen, Kathrine Røe
Meltzer, Sebastian
Ree, Anne Hansen
author_facet Abrahamsson, Hanna
Porojnicu, Alina C.
Lindstrøm, Jonas C.
Dueland, Svein
Flatmark, Kjersti
Hole, Knut H.
Seierstad, Therese
Moan, Johan
Redalen, Kathrine Røe
Meltzer, Sebastian
Ree, Anne Hansen
author_sort Abrahamsson, Hanna
collection PubMed
description BACKGROUND: Following curative-intent neoadjuvant therapy in locally advanced rectal cancer, metastatic progression is still dominant. We investigated if patients’ circulating 25-hydroxyvitamin D [25(OH)D] levels were associated with outcome. METHODS: Serum 25(OH)D concentration was assessed by liquid chromatography-mass spectrometry in samples collected from 84 patients at baseline, completion of the neoadjuvant therapy, and treatment evaluation before surgery, and analyzed with respect to season, disease presentation, and treatment effects. RESULTS: In the cohort of patients residing at latitude 58–62°N, baseline 25(OH)D differed significantly over the seasons, with highest measures (mean of 71.2 ± 5.6 nmol/L) in summer and lowest (48.7 ± 4.5 nmol/L) in spring, and changed over the three-month neoadjuvant period till response evaluation solely owing to season. The patient subgroup with slightly reduced performance status, anemia, and T4 disease that did not respond to the neoadjuvant therapy (ypT4 cases), had significantly lower baseline 25(OH)D (below 50 nmol/L) than T4 cases with response (ypT0–3) and T2–3 cases (above 60 nmol/L). Compared to the T4 patients with levels above 50 nmol/L, regarded as sufficient for a healthy bone status, those presenting levels below had significantly heightened risk of disease progression (mainly metastasis) and death, with hazard ratio of 3 and 17, respectively, on adjustment for age, sex, body mass index, and season. CONCLUSION: Rectal cancer T4 cases had high risk of metastatic progression and death if circulating 25(OH)D levels were insufficient but obtained short-term and long-term outcome to neoadjuvant treatment no worse than patients with T2–3 disease when 25(OH)D was sufficient. TRIAL REGISTRATION: ClinicalTrials.gov NCT00278694; registration date: 16 January 2006, retrospective to enrollment of the first 10 patients of the current report.
format Online
Article
Text
id pubmed-6533753
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65337532019-05-28 High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer Abrahamsson, Hanna Porojnicu, Alina C. Lindstrøm, Jonas C. Dueland, Svein Flatmark, Kjersti Hole, Knut H. Seierstad, Therese Moan, Johan Redalen, Kathrine Røe Meltzer, Sebastian Ree, Anne Hansen BMC Cancer Research Article BACKGROUND: Following curative-intent neoadjuvant therapy in locally advanced rectal cancer, metastatic progression is still dominant. We investigated if patients’ circulating 25-hydroxyvitamin D [25(OH)D] levels were associated with outcome. METHODS: Serum 25(OH)D concentration was assessed by liquid chromatography-mass spectrometry in samples collected from 84 patients at baseline, completion of the neoadjuvant therapy, and treatment evaluation before surgery, and analyzed with respect to season, disease presentation, and treatment effects. RESULTS: In the cohort of patients residing at latitude 58–62°N, baseline 25(OH)D differed significantly over the seasons, with highest measures (mean of 71.2 ± 5.6 nmol/L) in summer and lowest (48.7 ± 4.5 nmol/L) in spring, and changed over the three-month neoadjuvant period till response evaluation solely owing to season. The patient subgroup with slightly reduced performance status, anemia, and T4 disease that did not respond to the neoadjuvant therapy (ypT4 cases), had significantly lower baseline 25(OH)D (below 50 nmol/L) than T4 cases with response (ypT0–3) and T2–3 cases (above 60 nmol/L). Compared to the T4 patients with levels above 50 nmol/L, regarded as sufficient for a healthy bone status, those presenting levels below had significantly heightened risk of disease progression (mainly metastasis) and death, with hazard ratio of 3 and 17, respectively, on adjustment for age, sex, body mass index, and season. CONCLUSION: Rectal cancer T4 cases had high risk of metastatic progression and death if circulating 25(OH)D levels were insufficient but obtained short-term and long-term outcome to neoadjuvant treatment no worse than patients with T2–3 disease when 25(OH)D was sufficient. TRIAL REGISTRATION: ClinicalTrials.gov NCT00278694; registration date: 16 January 2006, retrospective to enrollment of the first 10 patients of the current report. BioMed Central 2019-05-23 /pmc/articles/PMC6533753/ /pubmed/31122213 http://dx.doi.org/10.1186/s12885-019-5724-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Abrahamsson, Hanna
Porojnicu, Alina C.
Lindstrøm, Jonas C.
Dueland, Svein
Flatmark, Kjersti
Hole, Knut H.
Seierstad, Therese
Moan, Johan
Redalen, Kathrine Røe
Meltzer, Sebastian
Ree, Anne Hansen
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
title High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
title_full High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
title_fullStr High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
title_full_unstemmed High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
title_short High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
title_sort high level of circulating vitamin d during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533753/
https://www.ncbi.nlm.nih.gov/pubmed/31122213
http://dx.doi.org/10.1186/s12885-019-5724-z
work_keys_str_mv AT abrahamssonhanna highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT porojnicualinac highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT lindstrømjonasc highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT duelandsvein highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT flatmarkkjersti highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT holeknuth highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT seierstadtherese highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT moanjohan highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT redalenkathrinerøe highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT meltzersebastian highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer
AT reeannehansen highlevelofcirculatingvitamindduringneoadjuvanttherapymaylowerriskofmetastaticprogressioninhighriskrectalcancer